Aurora Cannabis Inc. made a significant announcement on December 11, 2025. They launched a new product in Poland. This product is called Black Jelly. It is a proprietary medical cannabis cultivar. This launch expands Aurora’s portfolio. It specifically adds to their high-potency medical flower offerings. The move strengthens their presence in a key European market. Poland is known as one of Europe’s fastest-growing cannabis markets. Aurora has been active in Poland for many years. They previously introduced strains like Farm Gas and Sourdough. This demonstrates their ongoing strategic focus there.
Black Jelly is a notable new addition. It is a sativa-dominant hybrid. The cultivar boasts a potent cannabinoid profile. It contains approximately 27% THC. CBD levels are less than 1%. These are high levels for medical cannabis. The strain derives from impressive genetics. Its parent strains are Alien Cake 3030 and T037. This pedigree contributes to its unique characteristics. Patients can expect a rich aroma. It features notes of sweet black licorice. Fruity undertones also complement its profile. Visually, Black Jelly presents dense flowers. These flowers display attractive green and orange hues.
Aurora Cannabis prioritizes quality and consistency. Black Jelly is cultivated in their Canadian facilities. These facilities hold critical GACP and EU-GMP certifications. These standards ensure pharmaceutical-grade production. The company uses premium hang-drying techniques. Careful curing processes are also employed. These methods help preserve the terpene profile. They also maintain the flower’s overall quality. This meticulous approach aims to meet prescriber demand. Reliable, high-potency options are crucial. Aurora aims to consistently meet patient needs.
The Polish medical cannabis market is dynamic. Demand has grown significantly since 2017. Poland relies on imports for medical cannabis. Aurora is a major supplier to this market. This launch addresses the need for potent options. Industry analysts project substantial market growth. The market could reach over $27 million by 2030. Aurora’s strategy aligns with this expansion. They focus on high-margin medical sales. This positions them for future success. The company has extensive experience in global medical cannabis. They leverage this expertise across Europe. Aurora also operates facilities in Germany. This strengthens their European supply chain. This new product launch is more than just news. It is a step forward. It supports patient access to high-quality medicine. Aurora continues to build its reputation. They are seen as a trusted partner. This is true for physicians and patients alike. The cannabis industry often has trending developments. Related news on product innovation is common. This type of news is relevant for those following medical cannabis. Further updates on the market are anticipated.
